Abstract
Tamoxifen is the endocrine treatment of choice for hormone-responsive early and advanced breast cancer. Newly developed biodegradable luteinizing hormone-releasing hormone super agonists represent a practical and effective treatment for metastatic disease in premenopausal women. Progestins or aromatase inhibitors are useful therapies in patients who relapse from antiestrogens. Currently, there is no indication that improved survival can be achieved by combined endocrine therapy or combined chemo-hormonal therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 825-844 |
| Number of pages | 20 |
| Journal | Endocrinology and Metabolism Clinics of North America |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1991 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Fingerprint
Dive into the research topics of 'Pharmacologic manipulation of steroid hormones. Adjunctive therapies in cancer of the breast'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver